✦ LIBER ✦

172 Molecular mechanisms of the combination treatment of cetuximab and dasatinib in Kras mutant colorectal tumors

✍ Scribed by E.F. Dunn; M. Iida; R.A. Myers; C. Li; D.L. Wheeler

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6105 POSTER Phase II Trial of Temsirolim

✍ Spindler, K.G.; Sorensen, M.; Pallisgaard, N.; Andersen, R.F.; Lassen, U.; Havel 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB

Economic analysis of bevacizumab, cetuxi

✍ Lawrence, Donna; Maschio, Michael; Leahy, Kevin J.; Yunger, Simon; Easaw, Jacob 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 466 KB

Evaluation of the immune factors in the

✍ Zhu, Yanyun; Li, Jie; Jing, Fangfang; Ji, Tiefeng; Guo, Xiaoqin; Yang, Junlan; J 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 178 KB

Impact of the Specific Mutation in KRAS

✍ Modest, Dominik P.; Brodowicz, Thomas; Stintzing, Sebastian; Jung, Andreas; Neum 📂 Article 📅 2012 🏛 S. Karger AG 🌐 English ⚖ 225 KB

PCN70 Cost-Effectiveness of Cetuximab an

✍ Samyshkin, Y.; Hertel, N.; Griebsch, I. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

3617 POSTER Cost-Effectiveness of Cetuxi

✍ Samyshkin, Y.; Hertel, N.; Griebsch, I. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 39 KB